7.6 – References

  1. 1112. 1314. Nava-Mesa, M. O., eJimenez-Diaz, L., eYajeya, J. & Navarro-Lopez, J. D. GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer Disease. Frontiers in Cellular Neuroscience 8, (2014).
  2. 20113 Fetal Alcohol Spectrum Disorders FASD. CAMH https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/fetal-alcohol-spectrum-disorder.
  3. Alvarez, A., Opazo, C., Alarcón, R., Garrido, J. & Inestrosa, N. C. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J. Mol. Biol. 272, 348–361 (1997).
  4. Amarendran, V. & Abam, D. Benzodiazepines and opioids- A volatile combination. 26.
  5. Arenaza-Urquijo, E. M., Wirth, M. & Chételat, G. Cognitive reserve and lifestyle: moving towards preclinical Alzheimer’s disease. Front. Aging Neurosci. 7, (2015).
  6. Banerjee, S. et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378, 403–411 (2011).
  7. Carvajal, F. J. & Inestrosa, N. C. Interactions of AChE with Aβ Aggregates in Alzheimer’s Brain: Therapeutic Relevance of IDN 5706. Front. Mol. Neurosci. 4, (2011).
  8. Cholinesterase inhibitors | British Columbia Medical Journal. https://www.bcmj.org/articles/cholinesterase-inhibitors.
  9. Dou, X. et al. L1 coupling to ankyrin and the spectrin-actin cytoskeleton modulates ethanol inhibition of L1 adhesion and ethanol teratogenesis. The FASEB Journal 32, 1364–1374 (2018).
  10. Dou, X., Lee, J. Y. & Charness, M. E. Neuroprotective Peptide NAPVSIPQ Antagonizes Ethanol Inhibition of L1 Adhesion by Promoting the Dissociation of L1 and Ankyrin-G. Biological Psychiatry (2019) doi:10.1016/j.biopsych.2019.08.020.
  11. Gonzales, M. M. et al. Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. Int J Geriatr Psychiatry 33, 1305–1311 (2018).
  12. Gozes, I., Ivashko-Pachima, Y. & Sayas, C. L. ADNP, a Microtubule Interacting Protein, Provides Neuroprotection Through End Binding Proteins and Tau: An Amplifier Effect. Front Mol Neurosci 11, (2018).
  13. Gozes, I. NAP (Davunetide) Provides Functional and Structural Neuroprotection. https://www.ingentaconnect.com/content/ben/cpd/2011/00000017/00000010/art00009 (2011) doi:info:doi/10.2174/138161211795589373.
  14. Heimesaat, M. M., Giladi, E., Kühl, A. A., Bereswill, S. & Gozes, I. The octapetide NAP alleviates intestinal and extra-intestinal anti-inflammatory sequelae of acute experimental colitis. Peptides 101, 1–9 (2018).
  15. Ivashko-Pachima, Y., Maor-Nof, M. & Gozes, I. NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies. PLOS ONE 14, e0213666 (2019).
  16. Klimova, B., Maresova, P. & Kuca, K. Non-Pharmacological Approaches to the Prevention and Treatment of Alzheimer’s Disease with Respect to the Rising Treatment Costs. Curr. Alzheimer Res. 13, 1249–1258 (2016).
  17. Lanctôt, K. L., Rajaram, R. D. & Herrmann, N. Review: Therapy for Alzheimer’s disease: how effective are current treatments? Ther Adv Neurol Disord 2, 163–180 (2009).
  18. Lipton, S. A. The molecular basis of memantine action in Alzheimer’s disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2, 155–165 (2005).
  19. Mattson, M. P. et al. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376–389 (1992).
  20. Mechanism of action of antipsychotic drugs: (a) overproduction of dopamine; (b) antipsychotic medica – Biology Forums Gallery. https://biology-forums.com/index.php?action=gallery;sa=view;id=19650
  21. Pompili, M. et al. Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview. International Journal of Molecular Sciences 17, 1700 (2016).
  22. Seeman, P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 47, 27–38 (2002).
  23. Paterson, R. W. et al. Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alz Res Therapy 10, 32 (2018).
  24. Rafii, M. S. & Aisen, P. S. Recent developments in Alzheimer’s disease therapeutics. BMC Med 7, 7 (2009).
  25. Schelke, M. W. et al. Nutritional interventions for Alzheimer’s prevention: a clinical precision medicine approach. Annals of the New York Academy of Sciences 1367, 50–56 (2016).
  26. Waqar, M. & Batool, S. In silico analysis of binding interaction of conantokins with NMDA receptors for potential therapeutic use in Alzheimer’s disease. J Venom Anim Toxins Incl Trop Dis 23, 42 (2017).
  27. Yang, M.-H. et al. Reduction of aluminum ion neurotoxicity through a small peptide application – NAP treatment of Alzheimer’s disease. Journal of Food and Drug Analysis 27, 551–564 (2019).
  28. Yiannopoulou, K. G. & Papageorgiou, S. G. Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord 6, 19–33 (2013).
  29. Zhang, J. et al. Davunetide improves spatial learning and memory in Alzheimer’s disease-associated rats. Physiology & Behavior 174, 67–73 (2017).

License

Selected Topics in Health and Disease (2019 Edition) Copyright © by Dr. Ju. All Rights Reserved.

Share This Book